Kairu Therapeutics
Kairu Therapeutics is a biotechnology company developing oral, non-opioid small-molecule analgesics that target adrenergic receptor signaling with the goal of providing neuropathic pain relief without sedation or addiction. The organization is advancing a lead program toward an IND filing targeted for 2027 and is expanding a pipeline of adrenergic therapeutics across pain and perioperative care, supported by academic collaborations and preclinical pharmacology.
Industries
Nr. of Employees
small (1-50)
Products
Oral non-opioid analgesic candidate for neuropathic pain
A first-in-class oral small-molecule analgesic candidate designed to provide opioid-level efficacy in neuropathic pain without sedation or addiction; advancing toward an IND filing targeted for 2027.
Pipeline of adrenergic therapeutics for pain and perioperative care
A portfolio of next-generation adrenergic-based therapeutics being developed for multiple pain and neurobiology applications, including perioperative care.
Oral non-opioid analgesic candidate for neuropathic pain
A first-in-class oral small-molecule analgesic candidate designed to provide opioid-level efficacy in neuropathic pain without sedation or addiction; advancing toward an IND filing targeted for 2027.
Pipeline of adrenergic therapeutics for pain and perioperative care
A portfolio of next-generation adrenergic-based therapeutics being developed for multiple pain and neurobiology applications, including perioperative care.
Expertise Areas
- Analgesic drug discovery (non-opioid)
- Medicinal chemistry and selective receptor signaling
- Preclinical pharmacology and translational studies
- IND/regulatory submission planning
Key Technologies
- Adrenergic (α2A) receptor targeting
- Selective receptor signaling / biased signaling
- Small-molecule medicinal chemistry
- Preclinical pharmacology studies
News & Updates
The lead oral analgesic program is being advanced toward an Investigational New Drug (IND) filing targeted for 2027.
The lead oral analgesic program is being advanced toward an Investigational New Drug (IND) filing targeted for 2027.